Teradyne, Inc. (TER) Tops Q1 EPS by 2c; Guides Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts TER Hot Sheet
Price: $274.37 -7.38%
Financial Fact:
Selling and administrative: 78.79M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Selling and administrative: 78.79M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Teradyne, Inc. (NYSE: TER) reported Q1 EPS of $0.30, $0.02 better than the analyst estimate of $0.28. Revenue for the quarter came in at $397 million versus the consensus estimate of $382.33 million.
Teradyne, Inc. sees Q2 2012 EPS of $0.53-$0.62, versus the consensus of $0.37. Teradyne, Inc. sees Q2 2012 revenue of $490-$530 million, versus the consensus of $412.84 million.
For earnings history and earnings-related data on Teradyne, Inc. (TER) click here.
Teradyne, Inc. sees Q2 2012 EPS of $0.53-$0.62, versus the consensus of $0.37. Teradyne, Inc. sees Q2 2012 revenue of $490-$530 million, versus the consensus of $412.84 million.
For earnings history and earnings-related data on Teradyne, Inc. (TER) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
- BrightSpring Health Services, Inc. (BTSG) Tops Q3 EPS by 34c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
